Reduced leucocyte cholesteryl ester transfer protein expression in acute coronary syndromes

Journal of Internal Medicine

Volumn 264, Issue 6, 2008, Pages 571-585

  Ye, D ^a   Kraaijeveld, A O ^a,b   Grauss, R W ^b   Willems, S M ^b   Van Vark Van Der Zee, L C ^c   De Jager, S C A ^a   Jauhiainen, M ^d   Kuivenhoven, J A ^e   Dallinga Thie, G M ^e   Atsma, D E ^b   Hogendoorn, P C W ^b   Biessen, E A L ^a   Van Berkel, T J C ^a   Jukema, J W ^b   Van Eck, M ^a,f  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Acute coronary syndromes; CETP; HDL C; Ischemia; Leucocytes

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID A PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; GLYCERYL TRINITRATE; HEPARIN; MESSENGER RNA;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DOWN REGULATION; DRUG DOSE TITRATION; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSGENIC MOUSE; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ACUTE DISEASE; AGED; ANIMALS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; MODELS, ANIMAL;

EID: 55949107331     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2008.01997.x     Document Type: Article

References (38)

1. Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis 2000 153 : 263 72.
2. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med 1977 62 : 707 14.
3. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993 34 : 1255 74.
4. Agellon LB, Walsh A, Hayek T et al. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J Biol Chem 1991 266 : 10796 801.
5. Jiang XC, Agellon LB, Walsh A, Breslow JL, Tall AR. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. J Clin Invest 1992 90 : 1290 5.
6. Klerkx AHEM, de Grooth GJ, Zwinderman AH, Jukema JW, Kuivenhoven JA, Kastelein JJP. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest 2004 34 : 21 8.
7. Brousseau ME, O'Connor JJ Jr., Ordovas JM et al. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler Thromb Vasc Biol 2002 22 : 1148 54.
8. Hirano KS, Yamashita S, Kuga Y et al. Atherosclerotic disease in marked hypolipoproteinemia: combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vasc Biol 1995 15 : 1849 56.
9. Zhong S, Sharp DS, Grove JS et al. Increased coronary heart disease in Japanese-Am Men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996 97 : 2917 23.
10. Marcel YL, McPherson R, Hogue M et al. Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. J Clin Invest 1990 85 : 10 7.
11. Zhuang Y, Wang J, Qiang H, Li Y, Lui X, Li L. Serum cholesteryl ester transfer protein concentrations in healthy Chinese subjects and cardio-cerebrovascular disease patients. Clin Chim Acta 2001 305 : 19 25.
12. Boekholdt SM, Kuivenhoven JA, Wareham NJ et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation 2004 110 : 1338 40.
13. Faust RA, Tollefson JH, Chait A, Albers JJ. Regulation of LTP-I secretion from human monocyte-derived macrophages by differentiation and cholesterol accumulation in vitro. Biochim Biophys Acta 1990 1042 : 404 9.
14. Morton RE. Interaction of plasma-derived lipid transfer protein with macrophages in culture. J Lipid Res 1988 29 : 1367 77.
15. Tollefson JH, Faust R, Albers JJ, Chait A. Secretion of a lipid transfer protein by human monocyte-derived macrophages. J Biol Chem 1985 260 : 5887 90.
16. Van Eck M, Ye D, Hildebrand RB et al. Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice. Circ Res 2007 100 : 678 85.
17. Masucci-Magoulas L, Moulin P, Jiang XC et al. Decreased cholesteryl ester transfer protein (CETP) mRNA and protein and increased high density lipoprotein following lipopolysaccharide administration in human CETP transgenic mice. J Clin Invest 1995 95 : 1587 94.
18. Levels JHM, Pajkrt D, Schultz M et al. Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis. Biochim Biophys Acta 2007 1771 : 1429 38.
19. Brouwers GJ, Leebeek FWG, Tanck MWT, Jukema JW, Kluft C, de Maat MPM. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris: The APRAIS study. Thromb Haemost 2003 90 : 92 100.
20. Verheggen PW, de Maat MP, Cats VM et al. Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function. Eur Heart J 1999 20 : 567 74.
21. Kraaijeveld AO, de Jager SC, de Jager WJ et al. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation 2007 116 : 1931 41.
22. Niemeijer-Kanters SD, Dallinga-Thie GM, Ruijter-Heijstek FC et al. Effect of intensive lipid-lowering strategy on low-density lipoprotein particle size in patients with type 2 diabetes mellitus. Atherosclerosis 2001 156 : 209 16.
23. Drayna D, Jarnagin AS, McLean J et al. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature 1987 327 : 632 4.
24. Quinet E, Tall A, Ramakrishnan R, Rudel L. Plasma lipid transfer protein as a determinant of the atherogenicity of monkey plasma lipoproteins. J Clin Invest 1991 87 : 1559 66.
25. Quinet EM, Agellon LB, Kroon PA et al. Atherogenic diet increases cholesteryl ester transfer protein messenger RNA levels in rabbit liver. J Clin Invest 1990 85 : 57 363.
26. Pepys MB. Isolation of serum amyloid P-component (protein SAP) in the mouse. Immunology 1979 37 : 637 41.
27. van Amerongen MJ, Harmsen MC, van Rooijen N, Petersen AH, van Luyn MJA. Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am J Pathol 2007 170 : 818 29.
28. Merry L, Kyle W, Michael DB et al. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 2001 103 : 2181 7.
29. Jahangiri A, de Beer MC, de Beer FC. CETP Activity and Remodeling of Acute Phase HDL. Helsinki : 5th IAS workshop on HDL, 2007 (abstract).
30. Dedoussis GV, Panagiotakos DB, Louizou E et al. Cholesteryl ester-transfer protein (CETP) polymorphism and the association of acute coronary syndromes by obesity status in Greek subjects: the CARDIO2000-GENE study. Hum Hered 2007 63 : 155 61.
31. Hardardóttir I, Moser AH, Fuller J, Fielding C, Feingold K, Grünfeld C. Endotoxin and cytokines decrease serum levels and extra hepatic protein and mRNA levels of cholesteryl ester transfer protein in syrian hamsters. J Clin Invest 1996 97 : 2585 92.
32. Barter PJ, Brewer HB Jr., Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003 23 : 160 7.
33. Morehouse LA, Sugarman ED, Bourassa PA. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in NZW rabbits. J Lipid Res 2007 48 : 1263 72.
34. Brousseau ME, Schaefer EJ, Wolfe ML. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004 350 : 1505 15.
35. McKenney JM, Davidson MH, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 2006 48 : 1782 90.
36. Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 357 : 2109 22.
37. Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther 2006 111 : 893 908.
38. Krishna R, Anderson MS, Bergman AJ et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007 370 : 1907 14.